FDA
-
-
-
-
-
-
-
Vera Therapeutics (VERA) PT Raised to $95 at Goldman Sachs
-
-
-
-
-
-
-
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Evercore ISI Reiterates Outperform Rating on Vera Therapeutics (VERA)
-
-
-
-
-
-
-
Vera Therapeutics Inc. (VERA) Reports Q4, Provides Business Update
-
-
-
-
-
-
-
Vera Therapeutics (VERA) Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
-
-
-
-
-
-
-
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

